Clin Osteol 2003; 8(3): 89-91

Monitoring of salmon calcitonin treatmentReview articles

V. Zikán

A treatment with salmon calcitonin (sCT) reduces the risk of vertebral compression fractures. However, the efficacy of nasal sCT as an antiresorptive drug in reducing fracture risk is limited by its bioavailability and by the development of resistance to sCT treatment with continued use (escape phe­ nomenon). When monitoring the individual patients, the changes in BMD or biochemical markers of bone remodeling in response to sCT therapy are only modest and similar in magnitude to the measurement precision error. The main objective of serial BMD measurements is to identify patients with significant loss of BMD despite the treatment. The calcitonin load test (CLT) enables to assess the response of bone to the given dose and the applica­ tion form of sCT and can be used as a tool to identify patients that will profit from a continued treatment with sCT.

Keywords: calcitonin, calcitonin load test, bone markers, bone mineral density, monitoring.

Published: December 11, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zikán V. Monitoring of salmon calcitonin treatment. Osteologický bulletin. 2003;8(3):89-91.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Amann P, Rizzo (Suppl. 3):13-18.
    2. Sarkar S, Mitlak BH, Wong M, et al. Relationships between bone mineral dens and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002;17;1-10. Go to original source...
    3. Cummings SR, Black D, Barret vention. JAMA 1999;282:324-325. Go to original source...
    4. Štěpán J, Šmíd 1998;137:707-715.
    5. Chambers TJ, Moore A The sensitivity of isolated osteoclasts to mor transformation by calcitonin. J Clin Endocrinol Metab 1983;57:819-824. Go to original source...
    6. Yumita S, Nicholson GC, Rowe DJ, et al. Biphasic effect of calcitonin on tartr resistant acid phosphatase activity in isolated rat osteoclasts. J Bone Miner Res 1991;6:91-597. Go to original source...
    7. Zikán V, Štěpán JJ. Plasma type 1 collagen cross-linked C-telopeptide: a sensi ve marker of acute effects of salmon calcitonin on bone resorption. Clin Chim Ac­ ta 2002;316:63-69. Go to original source...
    8. O'Doherty DP, Bickerstaff DR, McCloskey EV, et al. A comparison of the acute effects of subcutaneous and intranasal calcitonin. Clin Sci Colch 1990;78: 215-219. Go to original source...
    9. Štěpán JJ, Vokrouhlická J. Comparison of biochemical markers of bone remodel­ ling in the assessment of the effects of ale teoporosis. Clin Chim Acta 1999;288:121-135. Go to original source...
    10. Kraenzlin ME, Seibel MJ, Trechsel U, et al. The effect of intranasal salmon cal tonin on postmenopausal bone turnover as assessed by biochemical markers: evi­ dence of maximal effect after 8 weeks of continuous treatment. Calcif Tissue Int 1996;58:216-220. Go to original source...
    11. Chesnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-276. Go to original source...
    12. Cranney A, Tugwell P, Zytaruk N, et al. Meta-analyses of therapies for postme­ nopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of post­ menopausal osteoporosis.Endocr Rev. 2002;23:540-551. Go to original source...
    13. Inoue D, Shih C, Galson DL, et al. Calcitonin-dependent down-regulation of the mouse C1a calcitonin receptor in cells of the osteoclast lineage involves a transc­ riptional mechanism. Endocrinology 1999;140:1060-1068. Go to original source...
    14. Wener JA, Gorton SJ, Raisz LG. Escape from inhibition or resorption in cultures of fetal bone treated with calcitonin and parathyroid hormone. Endocrinology 1972;90:752-759. Go to original source...
    15. Wada S, Martin TJ, Findlay DM Homologous regulation of the calcitonin recep­ tor in mouse osteoclast-like cells and human breast cancer T47D cells. Endocri­ nology 1995;136:2611-2621. Go to original source...
    16. Štěpán JJ., Zikán V. Calcitonin loading test to assess the sustained efficacy of s mon calcitonin. Osteoporosis Int 2002;13 (Suppl.1):54.
    17. Grauer A, Reinel HH, Ziegler R, et al. Neutralizing antibodies against calcitonin. Horm Metab Res 1993;25:486-488. Go to original source...
    18. Singer FR, Aldred JP, Neer RM, et al. An evaluation of antibodies and clinical re­ sistance to salmon calcitonin. J Clin Invest 1972;51:2331-2338. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.